ClinicalTrials.gg
Not yet recruitingNCT07755033Updated Aug 10, 2026

Personalized Nutritional Formula for ICU Patients: A Study on Prognosis and Multidimensional Health Markers

An interventional study of Individualized Enteral Nutrition Formula and Standard Enteral Nutrition Formula in Sepsis, Nutrition and Gut -Microbiota, sponsored by Chinese Medical Association. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Chinese Medical Association · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
1,200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to evaluate the effects of an individualized enteral nutrition formula on clinical outcomes in critically ill adult patients in the intensive care unit (ICU). Participants will be randomly assigned to one of two groups: the individualized nutrition group or the standard nutrition group. In the individualized group, the total daily amount of enteral nutrition will be calculated and adjusted daily based on the patient's resting energy expenditure (measured by indirect calorimetry) and serum protein levels. In the standard group, a fixed-dose formula will be administered according to routine clinical protocols recommended by current guidelines. The intervention will be initiated within 48 hours of ICU admission and continued for up to 14 days or until ICU discharge. The study will assess clinical prognosis, as well as changes in gut and pulmonary microbiota, serum metabolomics, and macronutrient balance. The findings may provide evidence for personalized nutrition strategies in critically ill patients.

02

Conditions studied

  • Sepsis
  • Nutrition
  • Gut -Microbiota

Keywords

  • Critical Illness
03

In context

Sepsis

2,416 studies on the registry are indexed under Sepsis; 541 are open to participants now.

This study's planned enrollment of 1,200 is above the median of 102 across 1,165 interventional studies indexed under Sepsis.

Browse Sepsis studies →

Lead sponsor

Chinese Medical Association is the lead sponsor of 40 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Critically ill patients admitted to the intensive care unit (ICU) who meet the indications for enteral nutrition support.

Age ≥ 18 years. APACHE II score > 8 at ICU admission. Expected ICU length of stay > 7 days.

Exclusion criteria

Exclusion Criteria:

Age \< 18 years. Pregnancy or lactation. Known allergy to any component of the enteral nutrition formula. Gastrointestinal bleeding, incomplete intestinal obstruction, or other conditions precluding full enteral nutrition.

Known severe thyroid dysfunction (e.g., thyrotoxic crisis, myxedema coma, or uncontrolled hyperthyroidism/hypothyroidism).

Chronic end-stage organ failure, including: (NYHA) Class IV heart failure, Class C cirrhosis, or Stage 5 chronic kidney disease (CKD).

Primary intestinal diseases (e.g., Crohn's disease, ulcerative colitis, or intestinal ), short bowel syndrome, or history of extensive small bowel resection (residual small intestine \< 100 cm).

Metabolic disorders that significantly affect nutritional metabolism (e.g., Sheehan's syndrome, or other conditions with major metabolic consequences) as determined by the investigator.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,200 participants (estimated)

Study arms

  • Experimental
    Individualized Nutrition Group

    The total daily dose of enteral nutrition will be adjusted dynamically according to the patient's daily metabolic measurements.

    Dietary Supplement: Individualized Enteral Nutrition Formula

  • Active comparator
    Standard Nutrition Group

    A standardized enteral nutrition formula will be provided following the routine clinical protocol as recommended by current guidelines.

    Dietary Supplement: Standard Enteral Nutrition Formula

Interventions

  • Dietary supplementIndividualized Enteral Nutrition Formula

    Individualized Enteral Nutrition Formula Based on Daily Metabolic Measurements

  • Dietary supplementStandard Enteral Nutrition Formula

    Standardized enteral nutrition formula will be administered according to the routine clinical protocol recommended by current guidelines.

06

What researchers measure

Primary outcomes

  1. Length of ICU Stay

    Total number of days from ICU admission to ICU discharge.

    Time frame: Up to 90 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Xi F, You Y, Ding W, Gao T, Cao Y, Tan S, Yu W. Association of longitudinal changes in skeletal muscle mass with prognosis and nutritional intake in acutely hospitalized patients with abdominal trauma: a retrospective observational study. Front Nutr. 2023 May 31;10:1085124. doi: 10.3389/fnut.2023.1085124. eCollection 2023. PubMed 37324740 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Jul 2027, 11 months later.

Of 301 non-industry interventional studies with no phase under Sepsis, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 11 months is below that.

Counting every sponsor, half of 324 studies reached it within 22 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2026
First posted
Aug 10, 2026
StartEst.
Jul 28, 2026
Primary completionEst.
Jul 27, 2027
CompletionEst.
Dec 31, 2028
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07755033
Lead sponsor
Chinese Medical Association
Responsible party
Juanhong Shen (Nanjing Drum Tower Hospital, Chinese Medical Association) — Principal investigator
First posted
Aug 10, 2026
Start date
Jul 28, 2026 (estimated)
Primary completion
Jul 27, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Aug 10, 2026

Study contacts

Ying Xu, MD
Contact
xuying.0110@163.com
+86 13505159362

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion